Medigene AG

Medigene successfully raises EUR 32.3 million in oversubscribed private placement

Business news for the stock market

Planegg (pta050/24.05.2018/23:55) - NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY APPLICABLE LAWS

Medigene AG (FSE: MDG1, Prime Standard, TecDAX) announces that it has successfully raised EUR 32.3 million in gross proceeds through a significantly oversubscribed private placement to institutional investors via an accelerated book building. Medigene issued 2,230,000 new shares from authorized capital, representing approximately 10% of the currently outstanding shares. Shares were allocated to institutional investors at a price of EUR 14.50 per share which represents a 2.3% discount to the last closing price. This financing will increase the total number of registered shares to 24,544,595.

Concomittantly, QVT Financial LP, USA, a major shareholder of Medigene, has agreed to sell 1,105,490 existing shares of Medigene in a secondary offering to institutional investors at the same price of EUR 14.50 per share as part of a general restructuring across all QVT funds. These shares were fully placed. After the completion of this transaction QVT, will hold over 4% of Medigene's total outstanding share capital (previously 9.5%), thus remaining a major shareholder of Medigene. Keith Manchester, Managing Director and Head of Life Sciences for QVT Financial, remains a member of Medigene's Supervisory Board.

Dr. Thomas Taapken, Chief Financial Officer of Medigene, comments: "We are very pleased to announce this significantly oversubscribed placement of new and existing shares. In addition to existing institutional shareholders, we were able to attract new healthcare focussed investors. The strong demand in this offering clearly highlights investor interest in our maturing T cell cancer immunotherapy development pipeline. We are grateful for this strong demonstration of confidence in Medigene as a global leader in T cell immunology."

The issuance of new shares was resolved by the Executive Management Board and the Supervisory Board of Medigene by today's resolutions.

Guggenheim Securities, LLC and Baader Bank AG acted as bookrunners and Bryan Garnier & Co. as lead manager.

DISCLAIMER
This publication may not be published, distributed or transmitted, directly or indirectly, in the United States, Canada, Australia or Japan or any other jurisdiction where such an announcement would be unlawful. The distribution of this announcement may be restricted by law in certain jurisdictions and persons into whose possession this document or other information referred to herein should inform themselves about and observe any such restriction. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.